Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.
- Net profit attributable to members rises 42.7% to A$51.7 million
- Revenue from contracts with customers reaches A$97.2 million
- Interim dividend increased to 25.0 cents per share, fully franked
- Net tangible assets per security improve to $1.93 from $1.33
- No changes in control of entities or joint ventures during the period
Strong Financial Growth
Pro Medicus Limited, a key player in the medical software sector, has announced a significant uplift in its half-year results for the six months ending 31 December 2024. The company reported a net profit attributable to members of A$51.7 million, marking a 42.7% increase compared to the previous corresponding period. This growth underscores the company’s effective execution of its business strategy amid a competitive healthcare technology landscape.
Revenue and Profitability Metrics
Revenue from contracts with customers reached A$97.2 million, reflecting steady demand for Pro Medicus’s software solutions. Underlying profit before tax, excluding currency fluctuations and fair value movements, stood at A$69.9 million. The reported profit before tax was A$73.3 million, demonstrating resilience despite a minor currency loss of A$414,000. These figures highlight the company’s strong operational performance and efficient cost management.
Dividend Increase Signals Confidence
In line with its robust earnings, Pro Medicus declared an interim dividend of 25.0 cents per share, fully franked, up from 18.0 cents in the prior corresponding period. The dividend record date is set for 28 February 2025, with payment scheduled for 21 March 2025. This increase not only rewards shareholders but also signals management’s confidence in sustained cash flow generation and future growth prospects.
Balance Sheet Strength and Stability
The company’s net tangible assets per security improved markedly to $1.93 from $1.33 a year earlier, reflecting a stronger balance sheet and enhanced shareholder value. Notably, there were no changes in control of entities or joint ventures during the period, indicating a stable corporate structure focused on organic growth.
Outlook and Market Position
While the report does not provide explicit forward guidance, the half-year results position Pro Medicus well to capitalize on ongoing demand for advanced medical imaging and healthcare IT solutions. Investors will be watching closely how the company navigates evolving market dynamics and competitive pressures in the coming months.
Bottom Line?
Pro Medicus’s strong half-year results and dividend hike set a positive tone, but sustaining momentum will be key.
Questions in the middle?
- What are the company’s growth strategies amid increasing competition in medical software?
- How will currency fluctuations impact future profitability?
- Are there plans for acquisitions or joint ventures to accelerate expansion?